Newsletter

Subscribe and receive updates on this company

Text STOCKS to 72727 for mobile alerts

We are excited to present Taxus Cardium Pharmaceuticals Group, Inc. (OTC: CRXM).

Full DD Report for CRXM

Recent News from (OTC: CRXM)

Taxus Cardium Announces Name Change To Gene Biotherapeutics
SAN DIEGO , Jan. 8, 2018 /PRNewswire/ -- Taxus Cardium Pharmaceuticals Group (Trading Symbol: CRXM) today announced plans to affect a name change from Taxus Cardium Pharmaceuticals Group Inc. to Gene Biotherapeutics Inc. The name change reflects the Company's plan to exclusively focus ...
Source: PR Newswire
Date: January, 08 2018 09:00
Excellagen® Receives USPTO Notice Of Allowance For A New Patent Application Covering Blood Platelet Activation & Endogeneous Growth Factor Release For Wound Repair And Tissue Regeneration
SAN DIEGO , June 13, 2017 /PRNewswire/ -- Taxus Cardium Pharmaceuticals Group Inc. (Trading Symbol: CRXM) and its operating unit Activation Therapeutics today announced that a Notice of Allowance has been received from the U.S. Patent and Trademark Office (USPTO) for a new patent app...
Source: PR Newswire
Date: June, 13 2017 09:00
Angionetics To Present At Marcum 2017 MicroCap conference In New York City
SAN DIEGO , June 12, 2017 /PRNewswire/ -- Angionetics Inc., a majority-owned subsidiary of Taxus Cardium Pharmaceuticals Group Inc. (Trading Symbol: CRXM), focused on the discovery, clinical and commercial development of Generx [Ad5FGF-4] cardiovascular and cerebral angiogenic gene t...
Source: PR Newswire
Date: June, 12 2017 09:00
Angionetics To Present At Globalization Of Research And Industrialization Of Bio-Medicine Summit 2017 In Shenzhen, China
SAN DIEGO , June 5, 2017 /PRNewswire/ -- Angionetics Inc., a majority-owned subsidiary of Taxus Cardium Pharmaceuticals Group Inc. (Trading Symbol: CRXM), focused on the Phase 3 clinical development of Generx [Ad5FGF-4] cardiovascular and cerebral angiogenic gene therapy, today announced ...
Source: PR Newswire
Date: June, 05 2017 09:00
Angionetics To Present At The Biotechnology Industry Organization CEO & Investor Conference At The Waldorf Astoria New York City
SAN DIEGO , Feb. 9, 2017 /PRNewswire/ -- Angionetics Inc., a majority-owned subsidiary of Taxus Cardium Pharmaceuticals Group Inc. (Trading Symbol: CRXM), focused on the Phase 3 clinical development of Generx [Ad5FGF-4] cardiovascular angiogenic gene therapy, today announced that Mr....
Source: PR Newswire
Date: February, 09 2017 09:00
FDA Grants Fast Track Designation To Angionetics' Generx Product Candidate, A One-Time Gene Therapy For Coronary Heart Disease
SAN DIEGO , Feb. 7, 2017 /PRNewswire/ --  Angionetics Inc., a majority-owned subsidiary of Taxus Cardium Pharmaceuticals Group Inc. (Trading Symbol: CRXM), today reported that the FDA has granted Fast Track designation for the Phase 3 clinical investigation of Generx [Ad5FGF-4] car...
Source: PR Newswire
Date: February, 07 2017 09:00
Angionetics Research Head Authors Scientific American Article on Therapeutic Angiogenesis as Potential New Treatment Approach for Ischemic Heart Disease
SAN DIEGO , Jan. 9, 2017 /PRNewswire/ -- An article titled "Heart Therapy," written by Gabor M. Rubanyi, M.D., Ph.D., co-founder of Angionetics Inc., a majority-owned subsidiary of Taxus Cardium Pharmaceuticals Group Inc. (OTCQB: CRXM), was published in the January 2017 edition of Scie...
Source: PR Newswire
Date: January, 09 2017 09:00
Angionetics To Present At Two San Francisco-Based Healthcare Conferences: The Biotech Showcase 2017 And The 10th Annual OneMed Forum
SAN DIEGO , Jan. 3, 2017 /PRNewswire/ -- Angionetics Inc., a wholly-owned subsidiary of Taxus Cardium Pharmaceuticals Group Inc. (Trading Symbol: CRXM), focused on the Phase 3 clinical development of Generx [Ad5FGF-4] angiogenic cardiovascular gene therapy, today announced that Mr. Chris...
Source: PR Newswire
Date: January, 03 2017 09:00
Taxus Cardium Announces Two Director Retirements Following A Decade Of Distinguished Service
SAN DIEGO , Dec. 14, 2016 /PRNewswire/ -- Taxus Cardium Pharmaceuticals Group Inc. (Trading Symbol: CRXM) today announced that Tyler Dylan-Hyde , Ph.D. and Mr. Lon Otremba have retired as directors of the Company's Board of Directors after a decade of service. "We all thank Dr. Dylan...
Source: PR Newswire
Date: December, 14 2016 09:00
Angionetics' Generx® [Ad5FGF-4] Gene Therapy Biologic Receives FDA Clearance For U.S. Phase 3 Clinical Study As A New, Single Dose, Treatment For Coronary Artery Disease
SAN DIEGO , Sept. 12, 2016 /PRNewswire/ -- Angionetics Inc., a majority-owned subsidiary of Taxus Cardium Pharmaceuticals Group Inc. (Trading Symbol: CRXM), today announced that the U.S. FDA Center for Biologics Evaluation and Research (CBER) has cleared the Angionetics' Generx® [Ad5...
Source: PR Newswire
Date: September, 12 2016 09:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-04-250.0950.090840.0950.09084600
2018-04-240.07420.07420.07420.0742946
2018-04-230.0950.090840.0950.09084662
2018-04-220.078350.07420.0950.07422,513
2018-04-210.078350.07420.0950.07422,513

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-04-2330066245.3172Short
2018-04-201,0002,51339.7931Short
2018-04-1130172141.7476Short
2018-04-1042284450.0000Short
2018-04-091,0001,60062.5000Short

* Short Mode

Short Analysis provided by Squeeze Report.


About Taxus Cardium Pharmaceuticals Group, Inc. (OTC: CRXM)

Logo for Taxus Cardium Pharmaceuticals Group, Inc. (OTC: CRXM)

Cardium Therapeutics is a health sciences and regenerative medicine company focused on the acquisition and strategic development of new and innovative bio medical product opportunities and businesses with the potential to address significant unmet medical needs that have definable pathways to commercialization, partnering and other economic monetizations. Cardium s current medical opportunities portfolio, which is focused on health sciences and regenerative medicine, includes the Tissue Repair Company, Cardium Biologics, and the Company s in house MedPodium Health Sciences healthy lifestyle product platform. The Company s lead commercial product Excellagen R topical gel for wound care management, has recently received FDA clearance for marketing and sale in the United States. Cardium s lead clinical development product candidate Generx R is a DNA based angiogenic biologic intended for the treatment of patients with myocardial ischemia due to coronary artery disease. In addition, consistent with its capital efficient business model, Cardium continues to actively evaluate new technologies and business opportunities. In July , Cardium completed the sale of its InnerCool Therapies medical device business to Royal Philips Electronics, the first asset monetization from the Company s biomedical investment portfolio.

 

 

 

Current Management

  • Christopher Reinhard / President, CEO
  • Tracy Kent / Business Affairs, Executive Director
  • Mira Habel / Corporate Controller
  • Bonnie Ortega / IR
  • Christopher Reinhard / Chairman

Current Share Structure

  • Market Cap: $1,367,862 - 03/15/2018
  • Authorized: 200,000,000 - 03/14/2018
  • Issue and Outstanding: 14,398,544 - 03/14/2018

 


Recent Filings from (OTC: CRXM)

Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: January, 09 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: January, 04 2018
Notification that form 10-Q will be submitted late
Filing Type: NT 10-QFiling Source: edgar
Filing Date: November, 15 2017
Notification that form 10-Q will be submitted late
Filing Type: NT 10-QFiling Source: edgar
Filing Date: August, 15 2017
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: July, 28 2017
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: July, 28 2017
Notification that form 10-Q will be submitted late
Filing Type: NT 10-QFiling Source: edgar
Filing Date: May, 16 2017
Notification that form 10-K will be submitted late
Filing Type: NT 10-KFiling Source: edgar
Filing Date: March, 30 2017
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: March, 21 2017
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: March, 06 2017

 

 


Daily Technical Chart for (OTC: CRXM)

Daily Technical Chart for (OTC: CRXM)


Stay tuned for daily updates and more on (OTC: CRXM)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: CRXM)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

Monsta Trader
@MonstaTrader

 

 


Disclaimer: Monsta Trader publishes reports providing information on selected companies. Monsta Trader is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. Monsta Trader accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in CRXM is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. Monsta Trader has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. Monsta Trader does not own any shares of CRXM and does not buy, sell, or trade any shares of CRXM. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2016 by Monsta Trader. All rights reserved. Our Full Disclaimer: http://monstatrader.com/disclaimer/

 

 

Release this Report to Investors

Via Email

Via Text

Important

If you would like to schedule the release please Contact Us and we will assist you otherwise we will release this report to investors 15 minutes after payment is received to allow the most current information to be updated before the report is sent. Interested in reaching more investors? Contact Us